Patient, disease, and HCT characteristics
| Patient and disease characteristics . | Blinatumomab treatment . | HCT characteristics . | Outcomes at last follow-up . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, y/sex . | Cytogenetics . | Disease status . | Pre- MRD, %MNC . | Post- MRD, %MNC . | Grade 3/4 toxicities . | Days to HCT prep* . | Days to HCT* . | Preparative regimen . | Graft source . | ANC >500, d . | Acute GVHD . | Chronic GVHD . | Post-HCT day . | Status . |
| 18/M | IKZF1 del | CR1 | 0.61 | Neg | None | 35 | 43 | Flu/Cy/TBI | UCB | 31 | No | No | 371 | CR |
| 2/F | Del chr7, loss of IKZF1 | CR1 | 0.53 | Neg | None | 22 | 30 | Bu/Flu/Mel | MSD, BM | 11 | No | No | 404 | REL→CR |
| 16/M | (9;22)(q34;q11.2), +5, del(7)(p10) | CR2 | 0.01 | Neg | None | 9 | 17 | Thio/Cy/LD TBI | MUD, BM | 15 | I | No | 243 | CR |
| 19/M | 46XY | CR1 | 0.20 | Neg | None | 19 | 24 | Thio/Cy/LD TBI | MUD, BM | 19 | No | No | 336 | CR |
| 14/M | Trisomy 10 | CR1 | 0.16 | Neg | None | 23 | 28 | Cy/TBI | Haplo sib, BM | 35 | I | No | 277 | CR |
| 17/M | Gain of 9; gain of ABL1 | CR2 | 0.07 | Neg | None | 20 | 25 | Cy/TBI | Haplo sib, BM | 30 | No | Extensive | 459 | CR |
| 16/F | 46XX | CR2 | 1.00 | Neg | None | 1 | 10 | Mel/TBI | UCB | 25 | No | No | 446 | CR |
| 2/F | KMT2A-R; t(11;19)(q23;p13.3) | CR2 | 0.10 | 0.15 | None | N/A | N/A | N/A | N/A | N/A | — | — | — | DOD |
| 9/F | 46,XX,inv(9)(p13p24) ; JAK2-R | CR1 | 5.40 | Neg | None | 15 | 23 | Cy/TBI | MUD, BM | 26 | III | Extensive | 416 | DOC; CR |
| 1/M | KMT2A-R; KMT2A-MLLT3 (AF9) | CR1 | 0.7 | Neg | Seizure | 7 | 20 | Cy/TBI | UCB | 18 | I | No | 134 | REL→CR |
| 0.5/F | KMT2A-R; t(4;11)(q21;q23) | CR1 | 2.18 | Neg | None | 13 | 20 | Cy/TBI | MSD, BM | 14 | I | No | 360 | REL→CR |
| 8/M | Trisomy 10 | CR1 | 0.26 | Neg | None | 22 | 31 | Cy/TBI | MUD, BM | 20 | I | Extensive | 649 | CR |
| 8/F | t(9;22)(q34;q11.2) and CRLF2-R | CR1 | 0.13 | Neg | None | 6 | 18 | Cy/TBI | MSD, BM | 19 | No | No | 193 | CR |
| 15/M | t(4;5)(q31;13) and del(13) | CR2 | 2.20 | Neg | None | 4 | 13 | Mel/Clo | MUD, PBSC | 15 | No | No | 749 | CR |
| 1.8/M | t(11,19)(q23;p13.3) KMT2A-R | CR1 | 0.01 | Neg | None | 6 | 18 | Thio/Mel | Haplo parent, PBSC | 12 | II | No | 350 | REL→CR |
| Patient and disease characteristics . | Blinatumomab treatment . | HCT characteristics . | Outcomes at last follow-up . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, y/sex . | Cytogenetics . | Disease status . | Pre- MRD, %MNC . | Post- MRD, %MNC . | Grade 3/4 toxicities . | Days to HCT prep* . | Days to HCT* . | Preparative regimen . | Graft source . | ANC >500, d . | Acute GVHD . | Chronic GVHD . | Post-HCT day . | Status . |
| 18/M | IKZF1 del | CR1 | 0.61 | Neg | None | 35 | 43 | Flu/Cy/TBI | UCB | 31 | No | No | 371 | CR |
| 2/F | Del chr7, loss of IKZF1 | CR1 | 0.53 | Neg | None | 22 | 30 | Bu/Flu/Mel | MSD, BM | 11 | No | No | 404 | REL→CR |
| 16/M | (9;22)(q34;q11.2), +5, del(7)(p10) | CR2 | 0.01 | Neg | None | 9 | 17 | Thio/Cy/LD TBI | MUD, BM | 15 | I | No | 243 | CR |
| 19/M | 46XY | CR1 | 0.20 | Neg | None | 19 | 24 | Thio/Cy/LD TBI | MUD, BM | 19 | No | No | 336 | CR |
| 14/M | Trisomy 10 | CR1 | 0.16 | Neg | None | 23 | 28 | Cy/TBI | Haplo sib, BM | 35 | I | No | 277 | CR |
| 17/M | Gain of 9; gain of ABL1 | CR2 | 0.07 | Neg | None | 20 | 25 | Cy/TBI | Haplo sib, BM | 30 | No | Extensive | 459 | CR |
| 16/F | 46XX | CR2 | 1.00 | Neg | None | 1 | 10 | Mel/TBI | UCB | 25 | No | No | 446 | CR |
| 2/F | KMT2A-R; t(11;19)(q23;p13.3) | CR2 | 0.10 | 0.15 | None | N/A | N/A | N/A | N/A | N/A | — | — | — | DOD |
| 9/F | 46,XX,inv(9)(p13p24) ; JAK2-R | CR1 | 5.40 | Neg | None | 15 | 23 | Cy/TBI | MUD, BM | 26 | III | Extensive | 416 | DOC; CR |
| 1/M | KMT2A-R; KMT2A-MLLT3 (AF9) | CR1 | 0.7 | Neg | Seizure | 7 | 20 | Cy/TBI | UCB | 18 | I | No | 134 | REL→CR |
| 0.5/F | KMT2A-R; t(4;11)(q21;q23) | CR1 | 2.18 | Neg | None | 13 | 20 | Cy/TBI | MSD, BM | 14 | I | No | 360 | REL→CR |
| 8/M | Trisomy 10 | CR1 | 0.26 | Neg | None | 22 | 31 | Cy/TBI | MUD, BM | 20 | I | Extensive | 649 | CR |
| 8/F | t(9;22)(q34;q11.2) and CRLF2-R | CR1 | 0.13 | Neg | None | 6 | 18 | Cy/TBI | MSD, BM | 19 | No | No | 193 | CR |
| 15/M | t(4;5)(q31;13) and del(13) | CR2 | 2.20 | Neg | None | 4 | 13 | Mel/Clo | MUD, PBSC | 15 | No | No | 749 | CR |
| 1.8/M | t(11,19)(q23;p13.3) KMT2A-R | CR1 | 0.01 | Neg | None | 6 | 18 | Thio/Mel | Haplo parent, PBSC | 12 | II | No | 350 | REL→CR |
BM, bone marrow; Bu, busulfan; chr, chromosome; Clo, clofarabine; Cy, cyclophosphamide; del, deletion; DOC, dead of complication; DOD, dead of disease; F, female; Flu, fludarabine; inv, inversion; Haplo, haploidentical; LD, low dose (200 cGy); M, male; MNC, mononuclear cell; Mel, melphalan; MSD, matched sibling donor; MUD, matched unrelated donor; N/A, not applicable; Neg, negative; PBSC, peripheral blood stem cell; R, rearrangement; REL, relapse of disease; t, translocation; sib, sibling; TBI, total body irradiation; Thio, thiotepa; UCB, umbilical cord blood.
Days to HCT prep represents the days from the end of blinatumomab infusion to start of myeloablative prep; Days to HCT represents the days from end of blinatumomab to day of stem cell infusion.